Monika Patre

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

Edith A. Perez, Carlos H. Barrios, W. Eiermann et al. · Journal of Clinical Oncology · 2017 · 408 citations · Full text

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · The Lancet Oncology · 2020 · 363 citations

Breast Oncology, Oncology, Pharmacology +7

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

Edith A. Perez, Carlos H. Barrios, W. Eiermann et al. · Cancer · 2019 · 106 citations · Full text

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D.W. Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2020 · 97 citations

Breast Oncology, Oncology, Lba15 Primary Results +8